Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1390-1402

  Wang, Xiao Feng ^a,e   Guan, Fang ^a   Ohkoshi, Emika ^b   Guo, Wanjun ^c   Wang, Lili ^a   Zhu, Dong Qing ^a   Wang, Sheng Biao ^a   Wang, Li Ting ^b   Hamel, Ernest ^d   Yang, Dexuan ^c   Li, Linna ^c   Qian, Keduo ^b   Morris Natschke, Susan L ^b   Yuan, Shoujun ^c   Lee, Kuo Hsiung ^b,f   Xie, Lan ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b University of North Carolina   (United States)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Urumqi General Hospital   (China)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 [N (5 METHOXY)INDOLINYL]QUINAZOLINE; 2 CHLORO 4 [N (6 METHOXY 2,3 DIHYDRO 4 OXOQUINOLINYL)]QUINAZOLINE; 2 CHLORO 4 [N (6 METHYL 3,4 DIHYDROQUINOLINYL)]QUINAZOLINE; 2 CHLORO 4 [N (7 METHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[B]AZEPINYL)]QUINAZOLINE; 2 CHLORO 4 [N (7 METHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPINYL)]QUINAZOLINE; 2 CHLORO 4 [N (7 METHOXY 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZINYL)]QUINAZOLINE; 2 METHYL 4 (1 METHYL 7 METHOXY 2 OXO 3,4 DIHYDROQUINOXALIN 4 YL)QUINAZOLINE; 2 METHYL 4 [N (6 METHYL 1,2,3,4 TETRAHYDROQUINOLINYL)]QUINAZOLINE; 2 METHYL 4 [N (7 METHOXY 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZINYL)]QUINAZOLINE; 4 (N CYCLOAMINO)PHENYLQUINAZOLINE DERIVATIVE; 4 [N (5 METHOXY)INDOLINYL] 2 METHYLQUINAZOLINE; 4 [N (6 BROMO 1,2,3,4 TETRAHYDROQUINOLINYL)] 2 METHYLQUINAZOLINE; 4 [N (6 METHOXY 2,3 DIHYDRO 4 OXOQUINOLINYL)] 2 METHYLQUINAZOLINE; 4 [N (7 METHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[B]AZEPINYL)] 2 METHYLQUINAZOLINE; 4 [N (7 METHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPINYL)] 2 METHYLQUINAZOLINE; 7 METHOXY 4 (2 METHYLQUINAZOLIN 4 YL) 3,4 DIHYDROQUINOXALIN 2(1H) ONE; ANTINEOPLASTIC AGENT; COLCHICINE; PACLITAXEL; PROPRANOLOL; QUINAZOLINE DERIVATIVE; TERFENADINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

ANIMALS; CELL PROLIFERATION; COLCHICINE; FEMALE; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MODELS, MOLECULAR; QUINAZOLINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 84896876455     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4016526     Document Type: Article

References (37)

1. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics Nat. Rev. Drug Discovery 2010, 9, 790-803
2. Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents Cancer Treat. Rev. 2011, 37, 63-74
3. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumor blood vessels Nat. Rev. Cancer 2005, 5, 423-435
4. Mason, R. P.; Zhao, D.; Liu, L.; Trawick, M. L.; Pinney, K. G. A perspective on vascular disrupting agents that interact with tubulin: Preclinical tumor imaging and biological assessment Integr. Biol. 2011, 3, 375-387
5. Wang, X. F.; Xie, L. Vascular disrpting agents targeting at tubulin: A novel class of antitumor drug J. Int. Pharm. Res. 2012, 39, 445-454
6. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W. P.; Straford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J. S.; McCrae, K. R.; Remick, S. C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phophate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res. 2002, 62, 3408-3416
7. Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M. B.; Mather, G.; Pleiman, C. M.; Kasibhatla, S.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of N -(4-methoxyphenyl)- N,2-dimethylquinazolin-4- amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration J. Med. Chem. 2009, 52, 2341-2351
8. Wang, X. F.; Tian, X. T.; Ohkoshi, E.; Qin, B. J.; Liu, Y. N.; Wu, P. C.; Hung, H. Y.; Hour, M. J.; Qian, K.; Huang, R.; Bastow, K. F.; Janzen, W. P.; Jin, J.; Morris-Natschke, L. S.; Lee, K. H.; Xie, L. Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents Bioorg. Med. Chem. Lett. 2012, 22, 6224-6228
9. Wang, X. F.; Ohkoshi, E.; Wang, S. B.; Hamel, E.; Bastow, K. F.; Morris-Natschke, S. L.; Lee, K. H.; Xie, L. Synthesis and biological evaluation of N -alkyl- N -(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors Bioorg. Med. Chem. 2013, 21, 632-642
10. Wang, X. F.; Wang, S. B.; Ohkoshi, E.; Wang, L. T.; Hamel, E.; Qian, K.; Morris-Natschke, S. L.; Lee, K. H.; Xie, L. N -Aryl-6-methoxy-1,2,3,4- tetrahydroquinolines: A novel class of antitumor agents targeting the colchicine site on tubulin Eur. J. Med. Chem. 2013, 67, 196-207
11. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004, 305, 1163-1167
12. Dehnhardt, C. M.; Venkatesan, A. M.; Chen, Z.; Ayral-Kaloustian, S.; Santos, O. D.; Santos, E. D.; Curran, K.; Follettie, M. T.; Diesl, V.; Lucas, J.; Geng, Y.; DeJoy, S. Q.; Petersen, R.; Chaudhary, I.; Brooijmans, N.; Mansour, T.; Arndt, K.; Chen, L. Design and synthesis of novel diaminoquinazolines with in vivo efficacy for β-catenin/T-cell transcriptional factor 4 pathway inhibition J. Med. Chem. 2010, 53, 897-910
13. Liu, F.; Barsyte-Lovejoy, D.; Allali-Hassani, A.; He, Y.; Herold, J. M.; Chen, X.; Yates, C. M.; Frye, S. V.; Brown, P. J.; Huang, J.; Vedadi, M.; Arrowsmith, C. H.; Jin, J. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines J. Med. Chem. 2011, 54, 6139-6150
14. 4 receptor inverse agonists using a scaffold hopping approach J. Med. Chem. 2008, 51, 7855-7865
15. Takahata, H.; Ohnishi, Y.; Takehara, H.; Tsuritani, K.; Yamazaki, T. A convenient synthesis of monocyclic β -lactams by means of solid-liquid phase transfer reactions Chem. Pharm. Bull. 1981, 29, 1063-1068
16. Anderson, K. W.; Tepe, J. J. The first intermolecular Friedel-Crafts acylation with β-lactams Org. Lett. 2002, 4, 459-461
17. Booher, R. N.; Kornfeld, E. C.; Smalstig, E. B.; Clemens, J. A. Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists J. Med. Chem. 1987, 30, 580-583
18. Iakovou, K.; Kazanis, M.; Vavayannis, A.; Bruni, G.; Romeo, M. R.; Massarelli, P.; Teramoto, S.; Fujiki, H.; Mori, T. Synthesis of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4-benzoxazine, β-adrenergic affinity, inotropic, chronotropic and coronary vasodilating activities Eur. J. Med. Chem. 1999, 34, 903-917
19. Gangjee, A.; Vasudevan, A.; Queener, S. F. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases1 J. Med. Chem. 1997, 40, 479-485
20. Dalence-Guzmán, M. F.; Berglund, M.; Skogvall, S.; Sterner, O. SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure Bioorg. Med. Chem. 2008, 16, 2499-2512
21. Pérez-Sayáns, M.; Somoza-Martín, J. M.; Barros-Angueira, F.; Diz, P. G.; Rey, J. M. G.; García-García, A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases Cancer Lett. 2010, 295, 135-143
22. Hung, H. Y.; Ohkoshi, E.; Goto, M.; Bastow, K. F.; Nakagawa-Goto, K.; Lee, K. H. Antitumor agents. 293. Nontoxic dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylenedioxybiphenyl-2,2′- dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs J. Med. Chem. 2012, 55, 5413-5424
23. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines J. Natl. Cancer Inst. 1990, 82, 1113-1117
24. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984-6991
25. Li, P. K.; Pandit, B.; Sackett, D. L.; Hu, Z.; Zink, J.; Zhi, J.; Freeman, D.; Robey, R. W.; Werbovetz, K.; Lewis, A.; Li, C. A. Thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule- stabilizing activities Mol. Cancer Ther. 2006, 5, 450-456
26. Zhang, Z.; Meng, T.; Yang, N.; Wang, W.; Xiong, B.; Chen, Y.; Ma, L.; Shen, J.; Miao, Z. H.; Ding, J. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation Int. J. Cancer 2011, 129, 214-224
27. Knossow, M.; Jourdain, I.; Lachkar, S. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
28. Dorléans, A.; Gigant, B.; Ravelli, R. B. G.; Mailliet, P.; Mikol, V.; Knossow, M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13775-13779
29. Sun, L. Q.; Zhu, L.; Qian, K.; Qin, B.; Huang, L.; Chen, C. H.; Lee, K. H.; Xie, L. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates J. Med. Chem. 2012, 55, 7219-7229
30. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. In Cancer: Principles and Practice of Oncology Updates; Devita, V. T.; Hellman, S.; Rosenberg, S. A., Eds.; J. B. Lippincott: Philadelphia, PA, 1989; pp 1-12.
31. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 1991, 83, 757-766
32. Houghton, P.; Fang, R.; Techatanawat, I.; Steventon, G.; Hylands, P. J.; Lee, C. C. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity Methods 2007, 42, 377-387
33. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-22
34. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Márquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-76
35. Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule assembly in the absence of added nucleotides Proc. Natl. Acad. Sci. U.S.A. 1973, 70, 765-768
36. Hamel, E.; Lin, C. M. Glutamate-induced polymerization of tubulin: Characteristics of the reaction and application to the large-scale purification of tubulin Arch. Biochem. Biophys. 1981, 209, 29-40
37. Bhattacharyya, B.; Wolff, J. Promotion of fluorescence upon binding of colchicine to tubulin Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 2627-2631